These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 12136370

  • 1. The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects.
    Yates RA, Tateno M, Nairn K, Ikegami A, Dane A, Kemp J.
    Eur J Clin Pharmacol; 2002 Jul; 58(4):247-52. PubMed ID: 12136370
    [Abstract] [Full Text] [Related]

  • 2. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
    Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J, Chittick G, Posner J, Rolan PE, Pack RW.
    Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
    [Abstract] [Full Text] [Related]

  • 3. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers.
    Yates R, Nairn K, Dixon R, Seaber E.
    J Clin Pharmacol; 2002 Nov; 42(11):1237-43. PubMed ID: 12412822
    [Abstract] [Full Text] [Related]

  • 4. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults.
    Dixon R, Engleman K, Kemp J, Ruckle JL.
    J Child Adolesc Psychopharmacol; 1999 Nov; 9(1):35-42. PubMed ID: 10357516
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers.
    Yates R, Nairn K, Dixon R, Kemp JV, Dane AL.
    J Clin Pharmacol; 2002 Nov; 42(11):1244-50. PubMed ID: 12412823
    [Abstract] [Full Text] [Related]

  • 6. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
    Seaber EJ, Peck RW, Smith DA, Allanson J, Hefting NR, van Lier JJ, Sollie FA, Wemer J, Jonkman JH.
    Br J Clin Pharmacol; 1998 Nov; 46(5):433-9. PubMed ID: 9833595
    [Abstract] [Full Text] [Related]

  • 7. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
    Rolan P.
    Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
    [Abstract] [Full Text] [Related]

  • 8. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
    Seaber EJ, Ridout G, Layton G, Posner J, Peck RW.
    Eur J Clin Pharmacol; 1997 Oct; 53(3-4):229-34. PubMed ID: 9476036
    [Abstract] [Full Text] [Related]

  • 9. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
    Peck RW, Seaber EJ, Dixon R, Gillotin CG, Weatherley BC, Layton G, Posner J.
    Br J Clin Pharmacol; 1997 Dec; 44(6):595-9. PubMed ID: 9431839
    [Abstract] [Full Text] [Related]

  • 10. The clinical pharmacokinetics of zolmitriptan.
    Dixon R, Warrander A.
    Cephalalgia; 1997 Oct; 17 Suppl 18():15-20. PubMed ID: 9399013
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
    Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW.
    Br J Clin Pharmacol; 1997 Mar; 43(3):273-81. PubMed ID: 9088582
    [Abstract] [Full Text] [Related]

  • 14. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan.
    Dixon R, French S, Kemp J, Sellers M, Leclerc V, Delvaux M, Rautureau J.
    J Clin Pharmacol; 1998 Aug; 38(8):694-701. PubMed ID: 9725544
    [Abstract] [Full Text] [Related]

  • 15. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
    Peck RW, Seaber EJ, Dixon RM, Layton GR, Weatherley BC, Jackson SH, Rolan PE, Posner J.
    Clin Pharmacol Ther; 1998 Mar; 63(3):342-53. PubMed ID: 9542478
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome p450 on its pharmacokinetics in healthy volunteers.
    Dixon R, French S, Kemp J, Sellers M, Yates R.
    Clin Drug Investig; 1998 Mar; 15(6):515-22. PubMed ID: 18370509
    [Abstract] [Full Text] [Related]

  • 18. Bioequivalence study of 2 orodispersible formulations of zolmitriptan 5 mg in healthy volunteers.
    Cánovas M, Canals M, Polonio F, Cabré F.
    Arzneimittelforschung; 2012 Oct; 62(10):482-6. PubMed ID: 22918855
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
    Cawello W, Kim SR, Braun M, Elshoff JP, Ikeda J, Funaki T.
    Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.